Rui Zhu

This inventor holds 20 USPTO granted patents and 21 published patent applications and 3 EPO patents, primarily in RNA Interference Technology. Top assignees: Arrowhead Pharmaceuticals, Inc., Sixth Streetlending Partners, as the Administrative Agent, Adarx Pharmaceuticals, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rui Zhu. Retrieved from https://idiyas.com/inventor/rui-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 21)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 31)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Madison, WI (US) (2020 - 2023)
Middleton, WI (US) (2019 - 2024)
San Diego, CA (US) (2022 - 2024)

Company Filing History:

17 out of 102

Arrowhead Pharmaceuticals, Inc.

patents

2 out of 4

Sixth Streetlending Partners, as the Administrative Agent

patents

1 out of 2

Adarx Pharmaceuticals, Inc.

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

RNAi Agents

Angiopoietin-Like 3

Alpha-1 Antitrypsin

Hepatitis B Virus

Beta-ENaC

Integrin Ligands

HIF-2 Alpha

APOC3

Asialoglycoprotein Receptor

Compositions

Methods of Use

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729377 - RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use (2026-09-08),

2. 12655428 - RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use (2026-06-16),

3. 12582668 - METHODS FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) (2026-03-24),

4. 12534728 - RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use (2026-01-27),

5. 12365899 - RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) (2025-07-22),

6. 12221610 - RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use (2025-02-11),

7. 12042509 - Prekallikrein-modulating compositions and methods of use thereof (2024-07-23),

8. 11884920 - Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use (2024-01-30),

9. 11597701 - Integrin ligands and uses thereof (2023-03-07),

10. 11590156 - RNAi agents for hepatitis B virus infection (2023-02-28),

11. 11517584 - RNAi agents for Hepatitis B virus infection (2022-12-06),

12. 11492624 - RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 (2022-11-08),

13. 11214802 - RNAi agents for inhibiting expression of alpha-ENaC and methods of use (2022-01-04),

14. 11214801 - RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) (2022-01-04),

15. 11203756 - Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use (2021-12-21),

Title: Celebrating the Innovations of Inventor Rui Zhu

Introduction

Rui Zhu is a distinguished inventor based in Middleton, WI, with an impressive portfolio of 15 patents to his name. His pioneering work primarily focuses on cutting-edge RNA interference (RNAi) technologies and their applications in treating various diseases, notably renal cell carcinomas. Through his innovative contributions, Zhu has made significant strides in the medical field.

Latest Patents

Among his latest patents, Rui Zhu has developed RNAi agents designed to inhibit the expression of the HIF-2 alpha gene. This invention encompasses novel double-stranded RNAi agents that can effectively target HIF-2 alpha (EPAS1) gene expression. The disclosure also covers pharmaceutical compositions containing these RNAi agents, which may be enhanced by targeting ligands that interact with integrins, enabling better delivery to cells, specifically targeting clear cell renal cell carcinoma (ccRCC) tumors. Furthermore, Zhu has patented prekallikrein-modulating compositions, which offer methods for altering the expression or activity of plasma prekallikrein. This innovation may help reduce PKK mRNA and protein levels in cells, presenting therapeutic potentials in related health conditions.

Career Highlights

Rui Zhu's career includes key positions at notable biotechnology firms, including Arrowhead Pharmaceuticals, Inc. and Adarx Pharmaceuticals, Inc. His work in these companies has furthered the development of RNAi technologies and other pharmaceutical innovations.

Collaborations

Throughout his professional journey, Rui Zhu has collaborated with talented coworkers, such as Zhen Li and Tao Pei. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and the development of groundbreaking solutions in the field of biomedicine.

Conclusion

Rui Zhu's contributions to the realm of medical research and biotechnology through his 15 patents mark him as an influential figure in the industry. His innovative advancements in RNAi agents and modulatory compositions stand to benefit numerous patients suffering from serious health conditions. As he continues to pave the way for future inventions, the impact of his work will undoubtedly shape the future of therapeutic treatments.

Profile summary based on public USPTO records.